Galderma Group (1GALD) Stock Overview

Operates as a dermatology company worldwide. More details

1GALD fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	5/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 47.6% below our estimate of its fair value

Earnings are forecast to grow 23.73% per year

Earnings grew by 165.4% over the past year

Risk Analysis

No risks detected for 1GALD from our risk checks.

1GALD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

117

US$21.53

66.5% undervalued

stuart_roberts's

Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Galderma Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Galderma Group
Historical stock prices
Current Share Price	CHF 168.00
52 Week High	CHF 189.00
52 Week Low	CHF 133.00
Beta	-0.11
1 Month Change	8.39%
3 Month Change	1.20%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	64.71%

Recent updates

Shareholder Returns

	1GALD	IT Pharmaceuticals	IT Market
7D	-3.4%	0.8%	1.2%
1Y	n/a	18.7%	30.0%

Return vs Industry: Insufficient data to determine how 1GALD performed against the Italian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 1GALD performed against the Italian Market.

Price Volatility

Is 1GALD's price volatile compared to industry and market?
1GALD volatility
1GALD Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	5.1%
10% most volatile stocks in IT Market	8.0%
10% least volatile stocks in IT Market	3.0%

Stable Share Price: 1GALD has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1GALD's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1981	7,676	Flemming Ornskov	www.galderma.com

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology.

Galderma Group AG Fundamentals Summary

How do Galderma Group's earnings and revenue compare to its market cap?
1GALD fundamental statistics
Market cap	€39.64b
Earnings (TTM)	€520.07m
Revenue (TTM)	€4.45b

76.2x

P/E Ratio

8.9x

P/S Ratio

Is 1GALD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1GALD income statement (TTM)
Revenue	US$5.24b
Cost of Revenue	US$1.63b
Gross Profit	US$3.61b
Other Expenses	US$3.00b
Earnings	US$613.00m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Jul 23, 2026

Earnings per share (EPS)	2.61
Gross Margin	68.86%
Net Profit Margin	11.70%
Debt/Equity Ratio	32.0%

How did 1GALD perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

17%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/20 21:58
End of Day Share Price	2026/04/20 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Galderma Group AG is covered by 31 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Gordon	Barclays
Yihan Li	Barclays
Bethan Davies	Berenberg

Galderma Group (1GALD) Stock Overview

Rewards

Risk Analysis

Looking to be second time lucky with a game-changing new product

Galderma Group AG Competitors

Recordati Industria Chimica e Farmaceutica

Sun Pharmaceutical Industries

Zoetis

Jiangsu Hengrui PharmaceuticalsLtd

Price History & Performance

Recent News & Updates

Galderma Group AG Launches Alastin Regenerating Skin Nectar with Trihex+

Galderma Reports Interim Data from Investigator-Initiated Trials on Sculptra and Restylane for Aesthetic Changes in Weight Loss and Menopause

Galderma Launches ALASTIN Signature Practices

Galderma Announces Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 with Moderate-To-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Restylane Contour for the Correction of Temple Hollowing

Galderma Group AG, Annual General Meeting, Apr 22, 2026

Recent updates

Galderma Group AG Launches Alastin Regenerating Skin Nectar with Trihex+

Galderma Reports Interim Data from Investigator-Initiated Trials on Sculptra and Restylane for Aesthetic Changes in Weight Loss and Menopause

Galderma Launches ALASTIN Signature Practices

Galderma Announces Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 with Moderate-To-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Restylane Contour for the Correction of Temple Hollowing

Galderma Group AG, Annual General Meeting, Apr 22, 2026

Full year 2025 earnings released: EPS: US$2.60 (vs US$0.97 in FY 2024)

Galderma Group AG Provides Earnings Guidance for the Full-Year of 2026

Galderma's Nemluvio (Nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis Up to Three Years

Galderma Announces Triple Approval of New Restylane Syringe in the EU, the U.S., and Canada

Galderma Group AG Announces the Appointment of Luigi La Corte as Chief Financial Officer, Effective May 1, 2026

Galderma Expands Restylane Portfolio in Japan with Launch of OBT Hyaluronic Acid Injectables Restylane Defyne™? and Refyne

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

Galderma Group AG to Report Fiscal Year 2025 Results on Mar 05, 2026

Galderma to Present Data on its Innovative and Industry-Leading Neuromodulator Portfolio

Galderma Releases New Clinical Data Confirms Nemluvio®? (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults with Chronic Pruritus Of unknown Origin

Now 21% undervalued

Less than half of directors are independent

Galderma Group AG to Report First Half, 2026 Results on Jul 23, 2026

Galderma Presents New Data from Its Injectable Aesthetics Portfolio and Pipeline

Galderma Receives U.S. FDA Approval for Restylane Lyft for the Enhancement of the Chin Profile

Less than half of directors are independent

Galderma Group AG Revises Earnings Guidance for the Full Year 2025

Less than half of directors are independent

Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

Galderma Launches Transformative Skincare Segment with Cetaphil's New Skin Activator Hydrating & Firming Line

Galderma's Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin

Galderma Announces Updates from Its Portfolio At the 34Th European Academy of Dermatology and Venereology Congress

Less than half of directors are independent

Galderma Introduces Cetaphil Nourishing Oil to Foam Cleanser

First half 2025 earnings released: EPS: US$0.82 (vs US$0.20 in 1H 2024)

Less than half of directors are independent

Galderma Group Ag Raises Earning Guidance for 2025

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction with Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Galderma Group AG Announces Departure of Thomas Dittrich as Chief Financial Officer

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients with Systemic Sclerosis and Chronic Pruritus of unknown Origin

Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis

Galderma’S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence (Nice) Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales

Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis

Shareholder Returns

Price Volatility

About the Company

Galderma Group AG Fundamentals Summary

Earnings & Revenue

Dividends

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources